@article{3078797,
    title = "ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer",
    author = "Koumarianou, A. and Makrantonakis, P. and Zagouri, F. and Papadimitriou, C. and Christopoulou, A. and Samantas, E. and Christodoulou, C. and Psyrri, A. and Bafaloukos, D. and Aravantinos, G. and Papakotoulas, P. and Baka, S. and Andreadis, C. and Alexopoulos, A. and Bompolaki, I. and Kampoli, Κ. and Liori, S. and Karvounis, K. and Ardavanis, A.",
    journal = "Breast Cancer Research and Treatment",
    year = "2020",
    volume = "182",
    number = "1",
    pages = "85-96",
    publisher = "Springer-Verlag",
    issn = "0167-6806, 1573-7217",
    doi = "10.1007/s10549-020-05677-4",
    keywords = "aspartate aminotransferase;  paclitaxel;  130-nm albumin-bound paclitaxel;  albuminoid;  epidermal growth factor receptor 2;  ERBB2 protein, human;  estrogen receptor;  paclitaxel;  progesterone receptor, adult;  age distribution;  aged;  Article;  backache;  bone metastasis;  cancer growth;  cancer survival;  clinical effectiveness;  clinical outcome;  dizziness;  drug safety;  dysesthesia;  dyspnea;  fatigue;  febrile neutropenia;  female;  Functional Assessment of Cancer Therapy Breast Instrument;  Greece;  heart infarction;  human;  hypocalcemia;  liver failure;  liver metastasis;  lung metastasis;  major clinical study;  metastatic breast cancer;  multicenter study;  multiple cycle treatment;  myalgia;  nausea;  neuritis;  neutropenia;  overall survival;  pleura effusion;  priority journal;  progression free survival;  prospective study;  quality of life;  quality of life assessment;  side effect;  treatment outcome;  treatment response;  vein insufficiency;  vestibular disorder;  vomiting;  breast tumor;  clinical trial;  follow up;  lobular carcinoma;  metabolism;  middle aged;  mortality;  Paget nipple disease;  pathology;  prognosis;  survival rate, Aged;  Albumins;  Breast Neoplasms;  Carcinoma, Ductal, Breast;  Carcinoma, Lobular;  Female;  Follow-Up Studies;  Humans;  Middle Aged;  Paclitaxel;  Prognosis;  Prospective Studies;  Quality of Life;  Receptor, ErbB-2;  Receptors, Estrogen;  Receptors, Progesterone;  Survival Rate",
    abstract = "Purpose: The efficacy of nab-paclitaxel in patients with metastatic breast cancer (MBC) has been demonstrated in randomized clinical trials. However, real-world evidence on effectiveness remains limited. Patients and methods: The primary objective of this multicenter prospective study was to assess the overall response rate (ORR) of patients with MBC treated with nab-paclitaxel. Secondary objectives included progression-free survival (PFS), overall survival (OS) and quality of life, assessed with the Functional Assessment of Cancer Therapy-Breast (FACT-B) instrument. Results: Eligible patients (N = 150; 36% with de novo MBC presentation) with a median age of 64.5 years were enrolled (86% were ER+, 33.3% (50/150) were ≥ 70 years of age and 53% were treated in the third or later line of treatment). A median of 6 cycles were administered but 26% of patients required dose reduction due to toxicity. The ORR was 26.7% [95% confidence interval (CI) 19.6–33.7], the median PFS was 6.2 months (95% CI 5.2–7.3), and the median OS 21.1 months (95% CI 17.2-not estimable). There was no statistical significant difference in the median PFS of patients < and ≥ 70 years of age. The patients’ baseline FACT-B total score remained unchanged. The serious and non-serious adverse event incidence rates were 13% and 48%, respectively. Conclusions: This prospective study provides further evidence on quality of life, efficacy, and safety of nab-paclitaxel in patients with MBC and sheds more light in special subpopulations such as the elderly and those treated beyond the second line. © 2020, Springer Science+Business Media, LLC, part of Springer Nature."
}